Leading U.S. gynecologists see significant medical need for Pharmanest’s drug candidate SHACT

Document -

Leading U.S. gynecologists see significant medical need for Pharmanest’s drug candidate SHACT

Millions of women are exposed to pain during gynecological procedures, including IUD (intrauterine device) placements. This is due to the lack of effective and user-friendly therapy for pain relief. The Swedish pharmaceutical company Pharmanest is developing a new pain relief treatment which recently received very positive reviews from leading gynecologists at a meeting of experts in the U.S.
  • License: © All rights reserved
    The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
  • File format: .pdf

Related content

Leading U.S. gynecologists see significant medical need for Pharmanest’s drug candidate SHACT

Millions of women are exposed to pain during gynecological procedures, including IUD (intrauterine device) placements. This is due to the lack of effective and user-friendly therapy for pain relief. The Swedish pharmaceutical company Pharmanest is developing a new pain relief treatment which recently received very positive reviews from leading gynecologists at a meeting of experts in the U.S.